Mary Ellen Coe Elected to Merck Board of Directors


January 29, 2019 4:30 pm ET

KENILWORTH, N.J.–(BUSINESS WIRE)–Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced that Mary Ellen Coe, president, Google Customer
Solutions, at Google Inc. will join the company’s Board of Directors
effective March 18, 2019. Ms. Coe will stand for election with the
company’s other directors in connection with Merck’s Annual Meeting of
Shareholders on May 28, 2019. With the addition of Ms. Coe, the Merck
board will include 13 members.

“We are pleased to welcome such a highly respected business leader in
technology as Ms. Coe to the Merck board and look forward to benefiting
from her deep understanding of the evolving digital marketplace. As the
health care system continues to evolve, Ms. Coe’s strategic perspective
and operational expertise at one of the world’s most innovative
companies will be a significant asset to Merck,” said Kenneth C.
Frazier, chairman and chief executive officer, Merck.

Ms. Coe currently serves as president of Google Customer Solutions at
Google where she oversees the global ads business for mid-market and
small businesses, serving millions of customers and thousands of
partners worldwide. Prior to joining Google in 2012, Ms. Coe was a
principal at the global consulting firm McKinsey & Co. and a leader of
the firm’s consumer marketing and sales practice in North America.
Earlier in her career, Ms. Coe worked in product marketing, advertising
and brand strategy. Ms. Coe is a member of the advisory board of the
Ross Business School at the University of Michigan, and served on the
board of Whole Foods Market, Inc., chairing the Nominations and
Governance Committee. Ms. Coe earned her Bachelor of Arts from the
University of Michigan-Ann Arbor.

About Merck

For more than a century, Merck, a leading global biopharmaceutical
company known as MSD outside of the United States and Canada, has been
inventing for life, bringing forward medicines and vaccines for many of
the world’s most challenging diseases. Through our prescription
medicines, vaccines, biologic therapies and animal health products, we
work with customers and operate in more than 140 countries to deliver
innovative health solutions. We also demonstrate our commitment to
increasing access to health care through far-reaching policies, programs
and partnerships. Today, Merck continues to be at the forefront of
research to advance the prevention and treatment of diseases that
threaten people and communities around the world – including cancer,
cardio-metabolic diseases, emerging animal diseases, Alzheimer’s disease
and infectious diseases including HIV and Ebola. For more information,
and connect with us on TwitterFacebookInstagram,
and LinkedIn.

Forward-Looking Statement of Merck & Co., Inc., Kenilworth, N.J., USA

This news release of Merck & Co., Inc., Kenilworth, N.J., USA (the
“company”) includes “forward-looking statements” within the meaning of
the safe harbor provisions of the U.S. Private Securities Litigation
Reform Act of 1995. These statements are based upon the current beliefs
and expectations of the company’s management and are subject to
significant risks and uncertainties. If underlying assumptions prove
inaccurate or risks or uncertainties materialize, actual results may
differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry
conditions and competition; general economic factors, including interest
rate and currency exchange rate fluctuations; the impact of
pharmaceutical industry regulation and health care legislation in the
United States and internationally; global trends toward health care cost
containment; technological advances, new products and patents attained
by competitors; challenges inherent in new product development,
including obtaining regulatory approval; the company’s ability to
accurately predict future market conditions; manufacturing difficulties
or delays; financial instability of international economies and
sovereign risk; dependence on the effectiveness of the company’s patents
and other protections for innovative products; and the exposure to
litigation, including patent litigation, and/or regulatory actions.

The company undertakes no obligation to publicly update any
forward-looking statement, whether as a result of new information,
future events or otherwise. Additional factors that could cause results
to differ materially from those described in the forward-looking
statements can be found in the company’s 2017 Annual Report on Form 10-K
and the company’s other filings with the Securities and Exchange
Commission (SEC) available at the SEC’s Internet site (

Pamela Eisele
(267) 305-3558

Teri Loxam
(908) 740-1986

Unsubscribe from email alerts